P1/2, N=32, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P1, N=42, Terminated, BeOne Medicines | N=75 --> 42 | Trial completion date: Dec 2027 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Apr 2026; This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors.

Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.

P2, N=0, Withdrawn, ImmunityBio, Inc. | N=20 --> 0 | Not yet recruiting --> Withdrawn

P2, N=0, Withdrawn, ImmunityBio, Inc. | N=20 --> 0 | Not yet recruiting --> Withdrawn

PROTAC LNPs were synthesized by modifying F1324 and pomalidomide aptamers onto LNPs via a covalent chemical reaction in a certain proportion...Overall, we developed a PROTAC that exhibited persistent and excellent BCL6 degradation ability in DLBCL, with an excellent safety profile. Thus, our BCL6 degrader provides a complementary approach to existing clinical‑stage candidates.

P2, N=90, Recruiting, Artiva Biotherapeutics, Inc. | N=17 --> 90

P1, N=10, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | N=34 --> 10 | Trial completion date: Mar 2031 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2026

A photocaged dibenzosilacycloheptyne (photo-DBSH) and the complementary azide were deployed to tag the oncoprotein ligands (i.e., (+)-JQ1 for BRD4 and Olaparib for PARP1) and the E3 ligase ligand (i.e., Pomalidomide for CRBN), respectively, for a proof-of-concept study and potential treatment for triple-negative breast cancer (TNBC). Further in zebrafish models, PCPTAC promoted BRD4 degradation leading to thinner yolk sac extension and achieved 94% tumor inhibition in HeLa xenografts. This split-and-photoclick strategy paves a new avenue for developing safer and more efficacious PROTACs with synergistic antitumor effects.

P1, N=20, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University

In combination with rhIL-2, exp_GAIA integrates endogenous NK activity with induction of long-lasting, CD8+T cell-dependent antitumor immunity via a CCR5-CCL3-NK-IFN-γ-CD8 pathway, reinforced ICD with CRT exposure. These findings support exp_GAIA+rhIL-2 as a new NK-based strategy for durable control of solid tumors.

P1, N=175, Recruiting, Masonic Cancer Center, University of Minnesota